English 
Español
In collaboration with GlobalBio Inc., UDIBI offers protein design and engineering services, which allow for the development of antibodies with the necessary characteristics for preclinical and clinical phases of pharmaceutical development. Our experienced team has over two decades of expertise in the field. Using advanced bioinformatics tools and modeling, we specialize in engineering antibody-based therapies.
As antibodies are complex molecules, the antibody engineering process involves three steps:
1
Sequence analysis
2
3D Modeling
3
In silico evaluation of developability
The mechanisms of action mediated by the Fc
Monoclonal antibodies exert their therapeutic effects through various mechanisms. By binding to the Fab region, they can exert neutralizing action, induce or directly block cellular apoptosis. Binding of the Fc domain of the antibody to effector cells or complement triggers an “effector function” that kills target cells or recruits other immune cells to generate a secondary response. IMAGE © Front Immunol. 2018 Jan 4;8:1751.
